Randomized controlled clinical trial comparing the efficacy and tolerability of aripiprazole and sodium valproate in the treatment of Tourette syndrome

Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009;67(6):475–83.

Qi Y, et al. Progress in genetic studies of Tourette's Syndrome. Brain Sci. 2017;7(10):134.

Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation. J Neurosci. 2011;31(35):12387–95.

Sun N, et al. Functional evaluations of genes disrupted in patients with Tourette's disorder. Front Psychiatry. 2016;7:11.

Ledonne A, Mercuri NB. Current concepts on the physiopathological relevance of dopaminergic receptors. Front Cell Neurosci. 2017;11:27.

Meunier CN, Chameau P, Fossier PM. Modulation of synaptic plasticity in the cortex needs to understand all the players. Front Synaptic Neurosci. 2017;9:2.

Hu W, Chen Z. The roles of histamine and its receptor ligands in central nervous system disorders: an update. Pharmacol Ther. 2017;175:116–32.

Unal D, Akdemir D. Neurobiology of Tourette Syndrome. Turk Psikiyatri Derg. 2016;27(4):275–85.

Parkin GM, et al. Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders. World J Psychiatry. 2018;8(2):51–63.

Aida T, et al. Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice. Neuropsychopharmacology. 2015;40(7):1569–79.

McGuire JF. Behavior THerapy for youth with Tourette disorder. J Clin Psychol. 2016;72(11):1191–9.

Roessner V, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173–96.

Simpson DM, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699–706.

Andrade P, Visser-Vandewalle V. DBS in Tourette syndrome: where are we standing now? J Neural Transm. 2016;123(7):791–6.

Sallee F, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(9):771–81.

Stefanoff P, Wolanczyk T. Validity and reliability of Polish adaptation of Yale Global Tic Severity Scale (YGTSS) in a study of Warsaw school children aged 12–15. Przegl Epidemiol. 2005;59(3):753–62.

Wang LJ, et al. The effectiveness of aripiprazole for tics, social adjustment, and parental stress in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2016;26(5):442–8.

Wang S, et al. Effects of Chinese herbal medicine Ningdong granule on regulating dopamine (DA)/serotonin (5-TH) and gamma-amino butyric acid (GABA) in patients with Tourette syndrome. Biosci Trends. 2012;6(4):212–8.

Zhu Y, et al. Comorbid behavioural problems in Tourette's syndrome are positively correlated with the severity of tic symptoms. Aust N Z J Psychiatry. 2006;40(1):67–73.

Zheng P, et al. Involvement of tryptophan hydroxylase 2 gene polymorphisms in susceptibility to tic disorder in Chinese Han population. Behav Brain Funct. 2013;9:6.

Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull. 1985;21(4):809–43.

Al-Dhaher Z, et al. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacol. 2016;26(5):458–70.

Yoo HK, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013;74(8):e772–e78080.